MET免疫组化是肺腺癌MET扩增或MET外显子14突变的不良筛查方法:来自肺癌突变联盟三机构队列的数据
研究基于肺癌突变联盟三机构队列,检测181例转移性肺腺癌组织的MET免疫组化(IHC)、MET扩增和MET外显子14(METex14)突变。MET IHC阳性71例(39%),MET扩增3例(2%),METex14突变2例(1%)。在71例IHC阳性病例中,仅1例(1%)MET扩增、2例(3%)METex14突变;IHC阴性病例中2/110(2%)MET扩增。结论认为MET IHC对MET扩增或METex14突变筛查效率低,后者最好通过FISH和多基因NGS panel检测。
要点
- 181例转移性肺腺癌中,MET IHC阳性率为39%(71/181),MET扩增仅2%(3/181),METex14突变仅1%(2/181)。
- 71例MET IHC阳性病例中,仅1例(1%)MET扩增、2例(3%)METex14突变。
- MET IHC阴性病例中2/110(2%)为MET扩增,提示IHC可能漏检MET扩增患者。
核心结论
- 在本研究中,几乎所有MET IHC阳性病例对MET扩增或METex14突变均为阴性。
- MET IHC也可能漏检MET扩增患者。
- 本队列中MET扩增病例数量有限,使得难以证明MET IHC与MET扩增之间的关联。
- 作者认为IHC似乎是这些基因组变化的不良筛查方法,MET扩增或METex14突变最好通过FISH和多基因NGS panel检测。
研究设计与样本
- 研究为来自肺癌突变联盟的三机构队列,所有患者均为转移性肺腺癌且未接受过靶向治疗。
- MET IHC阳性定义为使用SP44抗体H-score≥200。
- MET扩增定义为NGS拷贝数倍数变化≥1.8倍或FISH MET与7号染色体着丝粒比值>2.2。
- 共检测181例患者的组织用于MET IHC、MET扩增和METex14突变分析。
主要发现
- 181例中,MET IHC阳性71例(39%),MET扩增3例(2%),METex14突变2例(1%)。
- MET扩增病例中,2例FISH阳性,MET与7号染色体着丝粒比值分别为3.1和3.3;1例NGS阳性,倍数变化为4.4倍;3例中1例为MET IHC阳性。
- 71例IHC阳性病例中,1例(1%)MET扩增,2例(3%)METex14突变。
- MET IHC阴性病例中,2/110(2%)为MET扩增。
局限性
- 本队列中MET扩增病例数量有限,使得难以证明MET IHC与MET扩增之间的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: MNNG HOS Transforming gene (MET) amplification and MET exon 14 (METex14) alterations in lung cancers affect sensitivity to MET proto-oncogene, receptor tyrosine kinase (MET [also known by the alias hepatocyte growth factor receptor]) inhibitors. Fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and immunohistochemistry (IHC) have been used to evaluate MET dependency. Here, we have determined the association of MET IHC with METex14 mutations and MET amplification. METHODS: We collected data on a tri-institutional cohort from the Lung Cancer Mutation Consortium. All patients had metastatic lung adenocarcinomas and no prior targeted therapies. MET IHC positivity was defined by an H-score of 200 or higher using SP44 antibody. MET amplification was defined by copy number fold change of 1.8x or more with use of NGS or a MET-to-centromere of chromosome 7 ratio greater than 2.2 with use of FISH. RESULTS: We tested tissue from 181 patients for MET IHC, MET amplification, and METex14 mutations. Overall, 71 of 181 patients (39%) were MET IHC-positive, three of 181 (2%) were MET-amplified, and two of 181 (1%) harbored METex14 mutations. Of the MET-amplified cases, two were FISH positive with MET-to-centromere of chromosome 7 ratios of 3.1 and 3.3, one case was NGS positive with a fold change of 4.4x, and one of the three cases was MET IHC-positive. Of the 71 IHC-positive cases, one (1%) was MET-amplified and two (3%) were METex14-mutated. Of the MET IHC-negative cases, two of 110 (2%) were MET-amplified. CONCLUSIONS: In this study, nearly all MET IHC-positive cases were negative for MET amplification or METex14 mutations. MET IHC can also miss patients with MET amplification. The limited number of MET-amplified cases in this cohort makes it challenging to demonstrate an association between MET IHC and MET amplification. Nevertheless, IHC appears to be an inefficient screen for these genomic changes. MET amplification or METex14 mutations can best be detected by FISH and a multiplex NGS panel.
引用
- Guo R, Berry LD, Aisner DL, et al. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019. PMID: 31228623. doi:10.1016/j.jtho.2019.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。